A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications.
VP, P. & RN, T. (2026). A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications.. The Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.74.1350
VP P, RN T. A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications.. The Journal of the Association of Physicians of India. 2026; doi: 10.59556/japi.74.1350
VP P, RN T. A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications.[J]. The Journal of the Association of Physicians of India. 2026. DOI: 10.59556/japi.74.1350.
@article{vp2026,
author = {Parimi VP and Tejaswini RN},
title = {A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications.},
journal = {The Journal of the Association of Physicians of India},
year = {2026},
doi = {10.59556/japi.74.1350},
note = {PMID: 42543979},
}
TY - JOUR AU - Parimi VP AU - Tejaswini RN TI - A Complex Case of Systemic Sclerosis with Concurrent Breast Malignancy and Treatment-related Complications. T2 - The Journal of the Association of Physicians of India PY - 2026 DO - 10.59556/japi.74.1350 AN - PMID:42543979 ER -
Systemic sclerosis (SSc) is a complex autoimmune disease marked by vasculopathy, fibrosis, and multisystem involvement. Interstitial lung disease (ILD) and pulmonary hypertension (PH) are major mortality contributors. Importantly, SSc is associated with an increased risk of malignancy. This report presents a challenging case of SSc with severe Raynaud's phenomenon (RP), digital gangrene, calcinosis cutis, extensive ILD, severe PH, and right heart failure. The patient underwent mesenchymal stem cell therapy (MST), following which she developed breast cancer and chemotherapy-related complications, ultimately leading to death. This case highlights the need for timely intervention, screening for malignancy, and awareness of potential therapy-related risks in SSc.